罗氏控股公司报告称，受制药和诊断业务增长推动，第三季度销售额上升，该制药商正努力争取其新型乳腺癌和多发性硬化症药片的批准。
Roche Holding reported higher sales for the third quarter on growth in its pharmaceuticals and diagnostics units, as the drugmaker works to secure approval for its new breast-cancer and multiple-sclerosis pills.
该瑞士集团周四表示，第三季度销售额为161.3亿瑞士法郎（195.7亿美元），而去年同期为149.2亿瑞士法郎。Visible Alpha调查的分析师此前预测季度销售额为157.8亿瑞士法郎。
The Swiss group said Thursday that third-quarter sales came to 16.13 billion Swiss francs ($19.57 billion) compared with 14.92 billion francs for the same period last year. Analysts polled by Visible Alpha had forecast quarterly sales at 15.78 billion francs.
罗氏表示，剔除汇率变动影响后，销售额增长7%，其制药和诊断两个部门均有增长。
Roche said sales grew 7% when excluding currency changes, with increases in both its pharma and diagnostics divisions.
Ocrevus（用于多发性硬化症）、Hemlibra（用于血友病）和Vabysmo（用于眼部疾病）等畅销药销售额上升，帮助罗氏核心制药业务实现8%的营收增长，公司表示。与此同时，该集团诊断部门季度销售额上升5%，核心实验室和病理系统的需求抵消了中国医疗定价改革带来的冲击。
Higher sales for top-selling drugs such as Ocrevus for multiple sclerosis, Hemlibra for hemophilia, and Vabysmo for eye diseases helped Roche’s core pharma business deliver top-line growth of 8%, the company said. Meanwhile, the group’s diagnostics division posted a 5% rise in quarterly sales, with demand for core lab and pathology systems offsetting a hit from China’s healthcare-pricing reforms.
罗氏重申了全年指引，即剔除汇率变动影响后，销售额和核心每股收益均将增长。
Roche reiterated its full-year guidance, which calls for increases in both sales and core earnings per share when excluding currency movements.
该公司表示，已做好充分准备，将于今年晚些时候推出其乳腺癌药物吉瑞德斯特兰（giredestrant），并正接近批准其多发性硬化症药片费尼布鲁替尼（fenebrutinib）。
The company said it is fully prepared to launch its giredestrant breast-cancer pill later this year, and is nearing approval of its fenebrutinib tablet for multiple sclerosis.
请致函 Adrià Calatayud，邮箱：adria.calatayud@wsj.com
Write to Adrià Calatayud at adria.calatayud@wsj.com